NMDAR AUTOIMMUNE ENCEPHALITIS
Clinical trials for NMDAR AUTOIMMUNE ENCEPHALITIS explained in plain language.
Never miss a new study
Get alerted when new NMDAR AUTOIMMUNE ENCEPHALITIS trials appear
Sign up with your email to follow new studies for NMDAR AUTOIMMUNE ENCEPHALITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare brain diseases: drug trial targets severe inflammation
Disease control Recruiting nowThis study tests a drug called satralizumab in people with two rare autoimmune diseases that cause brain inflammation (NMDAR and LGI1 encephalitis). The goal is to see if it improves disability and reduces the need for emergency treatments. About 152 adults will receive either th…
Matched conditions: NMDAR AUTOIMMUNE ENCEPHALITIS
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Life after a rare brain disease: what happens to young patients Long-Term?
Knowledge-focused Recruiting nowThis study looks at the long-term social and emotional well-being of people who had NMDA receptor encephalitis, a rare brain disease. Researchers will use questionnaires to measure fatigue, anxiety, depression, sleep, and quality of life in 30 adults who are at least 18 years old…
Matched conditions: NMDAR AUTOIMMUNE ENCEPHALITIS
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated May 15, 2026 11:53 UTC